α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2016 May 27

PMID 27226637

Citations 40

Authors

Takayuki Oikawa

Takashi Nonaka

Makoto Terada

Akira Tamaoka

Shin-Ichi Hisanaga

Masato Hasegawa

Affiliations

Soon will be listed here.

Abstract

α-Synuclein is the major component of Lewy bodies and Lewy neurites in Parkinson disease and dementia with Lewy bodies and of glial cytoplasmic inclusions in multiple system atrophy. It has been suggested that α-synuclein fibrils or intermediate protofibrils in the process of fibril formation may have a toxic effect on neuronal cells. In this study, we investigated the ability of soluble monomeric α-synuclein to promote microtubule assembly and the effects of conformational changes of α-synuclein on Tau-promoted microtubule assembly. In marked contrast to previous findings, monomeric α-synuclein had no effect on microtubule polymerization. However, both α-synuclein fibrils and protofibrils inhibited Tau-promoted microtubule assembly. The inhibitory effect of α-synuclein fibrils was greater than that of the protofibrils. Dot blot overlay assay and spin-down techniques revealed that α-synuclein fibrils bind to Tau and inhibit microtubule assembly by depleting the Tau available for microtubule polymerization. Using various deletion mutants of α-synuclein and Tau, the acidic C-terminal region of α-synuclein and the basic central region of Tau were identified as regions involved in the binding. Furthermore, introduction of α-synuclein fibrils into cultured cells overexpressing Tau protein induced Tau aggregation. These results raise the possibility that α-synuclein fibrils interact with Tau, inhibit its function to stabilize microtubules, and also promote Tau aggregation, leading to dysfunction of neuronal cells.

Citing Articles

Co-Aggregation of TDP-43 with Other Pathogenic Proteins and Their Co-Pathologies in Neurodegenerative Diseases.

Jiang L, Zhang X, Hu H Int J Mol Sci. 2024; 25(22).

PMID: 39596445 PMC: 11594478. DOI: 10.3390/ijms252212380.

Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer's Disease and Other Proteinopathies.

Kotarba S, Kozlowska M, Scios M, Saramowicz K, Barczuk J, Granek Z Int J Mol Sci. 2024; 25(19).

PMID: 39409126 PMC: 11477428. DOI: 10.3390/ijms251910797.

Multivalency drives interactions of alpha-synuclein fibrils with tau.

Ramirez J, Saleh I, Yanagawa E, Shimogawa M, Brackhahn E, Petersson E PLoS One. 2024; 19(9):e0309416.

PMID: 39255305 PMC: 11386428. DOI: 10.1371/journal.pone.0309416.

Sex-Specific ADNP/NAP (Davunetide) Regulation of Cocaine-Induced Plasticity.

Toren Y, Ziv Y, Sragovich S, McKinney R, Barak S, Shazman S J Mol Neurosci. 2024; 74(3):76.

PMID: 39251453 PMC: 11384652. DOI: 10.1007/s12031-024-02234-2.

Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults.

Liu W, Li W, Liu Z, Wang X, Guo M, Wang S Alzheimers Res Ther. 2024; 16(1):103.

PMID: 38725083 PMC: 11084056. DOI: 10.1186/s13195-024-01463-2.

References

Fujishiro H, Tsuboi Y, Lin W, Uchikado H, Dickson D . Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol. 2008; 116(1):17-24. PMC: 2719249. DOI: 10.1007/s00401-008-0383-1. View

George J, Jin H, WOODS W, Clayton D . Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 1995; 15(2):361-72. DOI: 10.1016/0896-6273(95)90040-3. View

Anderson J, Walker D, Goldstein J, de Laat R, Banducci K, Caccavello R . Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006; 281(40):29739-52. DOI: 10.1074/jbc.M600933200. View

Lee F, Liu F, Pristupa Z, Niznik H . Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001; 15(6):916-26. DOI: 10.1096/fj.00-0334com. View

Ren Y, Liu W, Jiang H, Jiang Q, Feng J . Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem. 2005; 280(40):34105-12. DOI: 10.1074/jbc.M503483200. View

Giasson B, Forman M, Higuchi M, Golbe L, Graves C, Kotzbauer P . Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003; 300(5619):636-40. DOI: 10.1126/science.1082324. View

Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho W, Castillo P . Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000; 25(1):239-52. DOI: 10.1016/s0896-6273(00)80886-7. View

Maroteaux L, Campanelli J, Scheller R . Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988; 8(8):2804-15. PMC: 6569395. View

Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S . Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998; 18(2):106-8. DOI: 10.1038/ng0298-106. View

10.

Serpell L, Berriman J, Jakes R, Goedert M, Crowther R . Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A. 2000; 97(9):4897-902. PMC: 18329. DOI: 10.1073/pnas.97.9.4897. View

11.

Choi W, Zibaee S, Jakes R, Serpell L, Davletov B, Crowther R . Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 2004; 576(3):363-8. DOI: 10.1016/j.febslet.2004.09.038. View

12.

Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee V . Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002; 277(50):49071-6. DOI: 10.1074/jbc.M208046200. View

13.

Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Marti M . Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2013; 72(12):1203-12. DOI: 10.1097/NEN.0000000000000018. View

14.

Saito Y, Ruberu N, Sawabe M, Arai T, Tanaka N, Kakuta Y . Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol. 2004; 63(9):911-8. DOI: 10.1093/jnen/63.9.911. View

15.

Bertoncini C, Jung Y, Fernandez C, Hoyer W, Griesinger C, Jovin T . Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A. 2005; 102(5):1430-5. PMC: 547830. DOI: 10.1073/pnas.0407146102. View

16.

Yonetani M, Nonaka T, Masuda M, Inukai Y, Oikawa T, Hisanaga S . Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem. 2009; 284(12):7940-50. PMC: 2658087. DOI: 10.1074/jbc.M807482200. View

17.

Hasegawa M, Smith M, Goedert M . Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 1998; 437(3):207-10. DOI: 10.1016/s0014-5793(98)01217-4. View

18.

Crowther R, Jakes R, Spillantini M, Goedert M . Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 1998; 436(3):309-12. DOI: 10.1016/s0014-5793(98)01146-6. View

19.

Feany M, La Spada A . Polyglutamines stop traffic: axonal transport as a common target in neurodegenerative diseases. Neuron. 2003; 40(1):1-2. DOI: 10.1016/s0896-6273(03)00600-7. View

20.

Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J . Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging. 2014; 35(9):2180.e1-5. DOI: 10.1016/j.neurobiolaging.2014.03.024. View